DOPPS Practice Monitor to DOPPS.org
 
Last Data Update:  May 2021 (data through February 2021)
Featured Data
Browse All Data
News & Publications
About DPM
 Download Quality of Life Data Download All Featured Measures Slides (PPTX)   
Featured MeasureNational SampleKey MessagesRelated Slides
Dialysis Dose (Kt/V) Click here for full page slide Click Here to see information about Dialysis Dose (Kt/V) graph Click Here to see slides related to Dialysis Dose (Kt/V)
Hemoglobin Click here for full page slide Click Here to see information about Hemoglobin graph Click Here to see slides related to Hemoglobin
Serum Calcium Click here for full page slide Click Here to see information about Serum Calcium graph Click Here to see slides related to Serum Calcium
Serum Phosphorus Click here for full page slide Click Here to see information about Serum Phosphorus graph Click Here to see slides related to Serum Phosphorus
Serum PTH Click here for full page slide Click Here to see information about Serum PTH graph Click Here to see slides related to Serum PTH
Serum Potassium Click here for full page slide Click Here to see information about Serum Potassium graph Click Here to see slides related to Serum Potassium
IV Epoetin Dose (Received) Click here for full page slide Click Here to see information about IV Epoetin Dose (Received) graph Click Here to see slides related to IV Epoetin Dose (Received)
IV Iron Use Click here for full page slide Click Here to see information about IV Iron Use graph Click Here to see slides related to IV Iron Use
IV Vitamin D Use Click here for full page slide Click Here to see information about IV Vitamin D Use graph Click Here to see slides related to IV Vitamin D Use
Calcimimetic Use Click here for full page slide Click Here to see information about Calcimimetic Use graph Click Here to see slides related to Calcimimetic Use
  (Mouse-over icon to view, Click icon to browse)
Click To Open Slide Show
 
Understanding the DPM Figures   -   Share

SHARE





  

Browse All Data by Clinical Topic
  • Demographics
  • Diabetes/Cardiovascular
  • Anemia
  • Potassium
  • Dialysis Prescription and Dose
  • Mineral and Bone Disorder
  • Nutrition
  • Vascular Access
 Download Quality of Life Data
Browse All Data by Facility or Patient Characteristic
  • National sample
  • Hospital-based/Free-standing
  • Facility profit status
  • Race (Black/non-Black)
  • Dialysis Organization (DO) Size
  • Incident (<90d)/prevalent (90+d)
Copyright © 2021, Arbor Research Collaborative for Health.  |   |  Privacy Policy  |  Feedback?
Sign up here to receive communications from DOPPS
DOPPS Practice Monitor

  • Featured Data
  • Browse All Data
  • News and Publications
  • About DPM
  •  Browse
    • by Clinical Topic
      • Demographics
      • Diabetes/Cardiovascular
      • Anemia
      • Potassium
      • Dialysis Prescription and Dose
      • Mineral and Bone Disorder
      • Nutrition
      • Vascular Access
    • by Facility or Patient Characteristic
      • National sample
      • Hospital-based/Free-standing
      • Facility profit status
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
Download Quality of Life Data
Browse Data
Dialysis Dose (Kt/V)
Hemoglobin
Serum Calcium
Serum Phosphorus
Serum PTH
Serum Potassium
IV Epoetin Dose (Received)
IV Iron Use
IV Vitamin D Use
Calcimimetic Use

Dialysis Dose (Kt/V)

Key Messages: Kt/V is a measure of dialysis adequacy (dose) and related to the urea reduction ratio (URR). A QIP measure, the proportion of patients with Kt/V below 1.2 has remained <5% since December 2015.
SHARE

Hemoglobin

Key Messages: Hemoglobin levels are used to assess anemia. Since December 2015, the percentage of patients with hemoglobin above 12 g/dL has remained <16% (down from 31% in August 2010), the percentage with hemoglobin below 10 g/dL has increased to 24% (up from 8% in August 2010), and the percentage with hemoglobin below 9 g/dL has remained in the range of 6-7% (up from 3% in August 2010).
SHARE

Serum Calcium

Key Messages: Mineral and bone disorder (including abnormalities in serum calcium levels) is common in dialysis patients. Total calcium levels can be impacted by use of certain medications and dialysis therapies. No clear changes have been seen in serum calcium values during the DPM study period.
SHARE

Serum Phosphorus

Key Messages: Mineral and bone disorder (including abnormalities in serum phosphorus levels) is common in dialysis patients. Various factors are associated with serum phosphorus levels including nutritional intake, phosphate binder use, and serum PTH levels. No clear changes have been seen in serum phosphorus values during the DPM study period.
SHARE

Serum PTH

Key Messages: Mineral and bone disorder (including high levels of parathyroid hormone [PTH] in the blood) is common in dialysis patients. Injectable vitamin D and several oral medications are commonly used to lower PTH levels. Since December 2015, PTH levels have risen. The proportion of patients with PTH 150-600 pg/ml has decreased from 68% to 65%, and the proportion with PTH above 600 pg/ml has increased from 20% to 23%. The mean PTH in August 2019 was 489 pg/ml, and the median PTH value was 366 pg/ml.
SHARE

Serum Potassium

Key Messages: Clinical guidelines recommend maintaining serum potassium levels in the normal range, between 3.5 mEq/l and either 5.5 or 6.0 mEq/l. In August 2019, 83% of patients had potassium levels between 3.5 and 5.5 mEql, and 95% had levels between 3.5 and 6.0 mEq/l.
SHARE

IV Epoetin Dose (Received)

Key Messages: Since December 2015, the distribution of delivered IV epoetin dose has increased slightly, with 46% of patients receiving doses above 10,000 units/week. In August 2019, the mean delivered IV epoetin dose was 11,490 units/week (down 42% from 19,900 units/week in August 2010) and the median was 8,700 units/week (down 36% from 13,700 units/week in August 2010). The average weekly IV epoetin dose received is calculated based upon the actual amount administered to patients during a 30 day period prior, on average, to the mid-point of each month. Prescribed versus received epoetin doses may differ for various reasons including withholding or reducing the prescribed epoetin dose for a period of time.
SHARE

IV Iron Use

Key Messages: The percentage of patients prescribed IV iron at any time during the study month decreased from 80% in December 2015 to 74% as of August 2019.
SHARE

IV Vitamin D Use

Key Messages: Mineral and bone disorder (including abnormalities in serum PTH, calcium, and phosphorus levels) is common in dialysis patients. Injectable vitamin D medications are used to lower PTH levels. The percentage of patients prescribed IV vitamin D has steadily declined from 58% in December 2015 to 47% in August 2019. A concurrent rise in the use of oral vitamin D medications has been observed.
SHARE

Calcimimetic Use

Key Messages: Calcimimetic medications, including cinacalcet and etelcalcetide (approved in 2017), are used to lower PTH levels. Since December 2015, the proportion of patients with a calcimimetic prescription has gradually increased from 24% to 28% in August 2019.
SHARE

Share





Sign up here to receive communications from DOPPS
Copyright © 2021, Arbor Research Collaborative for Health.  |  Citation Advice  |  Privacy Policy  |  Feedback?

Citation Advice

We welcome you to use the data and graphics displayed on this website. We value the distribution of knowledge for the benefit of patient care and renal research. Please use the following citation as applicable: [Title/description of webpage]. The DOPPS Practice Monitor. [URL/Address of webpage being cited]. Accessed [insert date here]. Modifying DOPPS Practice Monitor data, tables, or graphics in any form is not permitted without prior approval from the DOPPS coordinating center staff at Arbor Research. You may contact us at DOPPS@ArborResearch.org

Quality of Life Data Download

Complete the form below to download a spreadsheet of patient-reported quality of life summary data and graphs from the DPM sample